GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jounce Therapeutics Inc (NAS:JNCE) » Definitions » Intangible Assets

Jounce Therapeutics (Jounce Therapeutics) Intangible Assets : $0.00 Mil (As of Dec. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Jounce Therapeutics Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Jounce Therapeutics's intangible assets for the quarter that ended in Dec. 2022 was $0.00 Mil.


Jounce Therapeutics Intangible Assets Historical Data

The historical data trend for Jounce Therapeutics's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jounce Therapeutics Intangible Assets Chart

Jounce Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Intangible Assets
Get a 7-Day Free Trial Premium Member Only - - - - -

Jounce Therapeutics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Jounce Therapeutics Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Jounce Therapeutics  (NAS:JNCE) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Jounce Therapeutics Intangible Assets Related Terms

Thank you for viewing the detailed overview of Jounce Therapeutics's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Jounce Therapeutics (Jounce Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
780 Memorial Drive, Cambridge, MA, USA, 02139
Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company has developed a suite of integrated technologies that comprise a Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.
Executives
Concentra Merger Sub, Inc. 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Concentra Biosciences, Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Richard /ca/ Murray director, officer: CEO and President 22643 WOODRIDGE CT, CUPERTINO CA 95014
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Hugh M Cole officer: Chief Business Officer C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Elizabeth Trehu officer: Chief Medical Officer C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Kimberlee C Drapkin officer: CFO and Treasurer PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Third Rock Ventures Iii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Jigar Raythatha director C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Third Rock Ventures Ii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
John Duncan Higgons director C/O AGIOS PHARMACEUTICALS, INC., 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Luisa Salter-cid director C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Gilead Sciences Inc 10 percent owner 333 LAKESIDE DR, FOSTER CITY CA 94404

Jounce Therapeutics (Jounce Therapeutics) Headlines

From GuruFocus

Jounce Therapeutics to Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 06-16-2022

Jounce Therapeutics Announces Restructuring

By sperokesalga sperokesalga 02-22-2023

Jounce Therapeutics to Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 05-27-2022